Sanofi boosts syringe and vacc capacity at French plant

By Gareth Macdonald

- Last updated on GMT

Related tags Sanofi-aventis Influenza vaccine Influenza Sanofi

Sanofi Aventis has revamped operations at its sterile injectables plant in Le Trait, France, adding three new production units that double syringe making capacity and diversify its vaccine manufacturing capability.

The expansion is primarily designed to boost production of prefilled syringes for the low molecular-weight heparin product Lovenox, demand for which is growing at around 13 per cent a year according to the French major.

Speaking at the unveiling ceremony late last week, Sanofi CEO Christopher Viehbacher, said: “Le Trait is one of many examples of Sanofi-aventis’ desire to invest in France in order to be able to meet worldwide public health challenges​.”

Viehbacher explained that over 90 per cent of the million syringes made at the facility each day are exported, with around 25 per cent being shipped to the US.

The investment has also expanded the range of vaccine production and manufacturing operations Sanofi can undertake at the plant.

While the facility already makes the seasonal influenza vaccine Vaxigrip in collaboration with the firm’s Sanofi Pasteur unit, starting later this month will begin packaging an infant meningitis for the Japanese market.

Additionally, Sanofi will begin making its intradermal influenza vaccine Intanza early next year.

“Operator-free” containment

The €87m ($127m) expansion includes new filling, inspection and syringe packaging lines as well as innovative, “operator-free” isolation technology to prevent contamination during manufacturing operations.

The “operator-free” approach is borrowed from safety and containment principles employed in the nuclear industry which, according to Sanofi, are being applied in a number of sectors, citing French carmaker Renault as an example.

The firm also highlighted the addition of electron beam (e-beam) sterilisation technology to the product filling lines installed at the facility, which it believes will offer a way of accelerating manufacture by reducing the time its takes to decontaminate components during the process.

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more